Opthea becomes ASX top 300 company

Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met primary end points in the latest clinical trial for diabetic macular edema (DME). Read more

OA hails success of inaugural virtual conference

Optometry Australia (OA) has hinted at a follow-up to the inaugural Optometry Virtually Connected event after attracting 2,200 registered delegates to become one of the largest optometric clinical conferences and trade shows in the region. Read more